The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...

CHICAGO -- A fixed-dose inhaler combining an inhaled corticosteroid, long-acting muscarinic antagonist, and long-acting beta agonist (ICS/LAMA/LABA) improved lung function and reduced exacerbations in ...

The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease. The American Thoracic Society (ATS) has released ...

Please provide your email address to receive an email when new articles are posted on . This analysis spanned from 2016 to 2022. Nearly 50% of patients were initially prescribed LABA/inhaled ...

In patients with chronic obstructive pulmonary disease (COPD), new initiation of beta2-agonist therapy, such as short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), or inhaled ...

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies. Jeffrey D. Dunn, PharmD, MBA: ICSs [inhaled corticosteroids] haven’t shown much evidence in impacting the course of ...

ATS 2024, San Diego – Only 14.5 percent of adult patients with moderate or severe asthma are prescribed the recommended SMART combination inhaler regimen and over 40 percent of academic pulmonary and ...

I really didn't see the death of short-acting beta-agonists (SABAs) coming. Sure, I'd read the SYGMA trials, [1,2] and yes, I was aware of lobbying from the "other side of the pond" (Europe). [3] So I ...

Researchers have found that the inclusion of a third drug to commonly used dual-drug inhalers can reduce asthma exacerbations and improve control over the disease in children, adolescents, and adults ...